tbResList Print — Gala Galantamine

Filters: qv=344, qv2=%, rfv=%

Product

Gala Galantamine
Description: <b>Galantamine</b><br>
FDA approved drug for mild to moderate Alzheimer's Disease<br>
- AChE inhibitor (reversible, competitive)<br>
-May improve memory, cognition, and behavior<br>
<br>

Pathway results for Effect on Cancer / Diseased Cells

Total Targets: 0

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↑, 1,   ROS↓, 2,  

Transcription & Epigenetics ⓘ

Ach↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2?, 1,   Inflam↓, 2,   NF-kB↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 3,   BChE↓, 1,   BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 3,   memory↑, 1,  
Total Targets: 14

Research papers

Year Title Authors PMID Link Flag
2024Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's diseaseKumar Gajendra—https://www.sciencedirect.com/science/article/pii/S27724174240002680
2024A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics StudyEvdokiya Salamanova—https://www.ddg-pharmfac.net/ddg/publications_files/2024_Chemistry.pdf0
2021A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative DisordersRumyana SimeonovaPMC8037483https://pmc.ncbi.nlm.nih.gov/articles/PMC8037483/0
2020Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancementMaju Mathew Koola—https://www.sciencedirect.com/science/article/abs/pii/S01651781203110820